SPTLC1 and amyotrophic lateral sclerosis: Recently, two independent studies reported patients with SPTLC1 variants who present with a juvenile-onset ALS (Johnson et al., 2021; Mohassel et al., 2021), providing a direct link between sphingolipid metabolic dysfunction and the pathogenesis of ALS.